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ARTICLE
Itraconazole Increases Ibrutinib Exposure 10-Fold and 
Reduces Interindividual Variation—A Potentially Beneficial 
Drug-Drug Interaction
Tuija Tapaninen1,2,† , Aleksi M. Olkkola1,2,†, Aleksi Tornio1,2 , Mikko Neuvonen1,2, Erkki Elonen3, Pertti J. Neuvonen1 , 
Mikko Niemi1,2  and Janne T. Backman1,2,*
The oral bioavailability of ibrutinib is low and variable, mainly due to extensive first-pass metabolism by cytochrome P450 
(CYP) 3A4. The unpredictable exposure can compromise its safe and effective dosing. We examined the impact of itracona-
zole on ibrutinib pharmacokinetics. In a randomized crossover study, 11 healthy subjects were administered itraconazole 
200 mg or placebo twice on day 1, and once on days 2–4. On day 3, 1 hour after itraconazole (placebo) and breakfast, ibrutinib 
(140 mg during placebo; 15 mg during itraconazole) was administered. Itraconazole increased the dose-adjusted geometric 
mean area under the concentration-time curve from zero to infinity (AUC0–∞) of ibrutinib 10.0-fold (90% confidence interval 
(CI) 7.2–13.9; P < 0.001) and peak plasma concentration (Cmax) 8.8-fold (90% CI 6.3–12.1; P < 0.001). During itraconazole, the 
intersubject variation for the AUC0–∞ (55%) and Cmax (53%) was around half of that during placebo (104%; 99%). In conclu-
sion, itraconazole markedly increases ibrutinib bioavailability and decreases its interindividual variability, offering a pos-
sibility to improved dosing accuracy and cost savings.
Ibrutinib is a potent Bruton’s tyrosine kinase (BTK) inhibi-
tor used in the treatment of chronic lymphocytic leukemia 
(CLL), Waldenström’s macroglobulinemia, certain lym-
phomas, and chronic graft-vs.-host disease.1–3 Despite 
substantial efficacy in treating patients with CLL, the use 
of ibrutinib is limited by its high cost. Owing to extensive 
first-pass metabolism, its mean oral bioavailability in the 
fasted state is only about 3%.3,4 The majority of ibrutinib is 
metabolized by cytochrome P450 (CYP) 3A4 in the intestine 
and liver.5 Its main metabolite, PCI-45227, has an inhibitory 
activity toward BTK about 15 times lower than that of parent 
ibrutinib.3 The pharmacokinetics of ibrutinib displays sub-
stantial intersubject variability, which may explain some of 
its adverse effects.4–6
The exposure to ibrutinib is greatly increased by CYP3A4 
inhibitors.3 Moreover, food enhances the bioavailability of 
ibrutinib about twofold, probably by increasing hepatic blood 
flow and thereby decreasing hepatic extraction.4,7 Under fed 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Ibrutinib is an expensive drug used against B-cell 
malignancies. Its oral bioavailability is low, varia-
ble, and dependent on cytochrome P450 (CYP) 3A4 
 activity. The use of strong CYP3A4 inhibitors with 
ibrutinib is recommended to be avoided. Effect of itra-
conazole on ibrutinib exposure has not been studied 
in humans.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  Our hypothesis was that itraconazole used with a small 
ibrutinib dose increases ibrutinib plasma concentrations 
to the same level as the nearly 10-fold higher ibrutinib 
dose alone and decreases intersubject variation.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  Itraconazole increased ibrutinib exposure, on average, 
10-fold and diminished the intersubject variation in ibruti-
nib exposure by about 50%.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
✔  Concomitant use of itraconazole allows reduction of 
ibrutinib dose roughly by 90% and reduces intersubject 
variation in ibrutinib concentrations. Significant cost- 
savings (US >  $10,000 dollars/patient/year) could be 
achieved by using itraconazole as a booster with ibrutinib. 
In addition, the risk of fungal infections could be dimin-
ished by using itraconazole with ibrutinib.
346
Clinical and Translational Science
Itraconazole Increases Ibrutinib Exposure
Tapaninen et al.
conditions, the intestinal CYP3A4-inhibitor, grapefruit juice, 
increased the area under the plasma concentration-time 
curve (AUC) of ibrutinib 2.2-fold in healthy adults.4 In a fasted 
state, the CYP3A4-inhibitor ketoconazole raised the AUC of 
ibrutinib 24-fold in healthy volunteers.6 Furthermore, in pa-
tients with B-cell malignancy, erythromycin and voriconazole 
increased the exposure to ibrutinib 3.0-fold and 5.7-fold in a 
nonfasted state, respectively.8
Currently, it is recommended to avoid the concomitant 
use of strong CYP3A4 inhibitors with ibrutinib, unless the 
benefit outweighs the risk.3 However, at least theoretically, 
the interaction between a strong CYP3A4 inhibitor and 
ibrutinib could be useful in reducing the required dose of 
ibrutinib, and, therefore, the financial burden of the treat-
ment, and in decreasing the high interindividual variability 
seen in the pharmacokinetics of ibrutinib. The antifungal 
agent itraconazole is a strong inhibitor of CYP3A4 with fa-
vorable tolerability and absorption properties compared with 
ketoconazole.9,10 However, there is only a physiologically- 
based pharmacokinetic modeling-based estimate of the in-
fluence of itraconazole on ibrutinib pharmacokinetics, and 
clinical data are lacking.11
This randomized placebo-controlled crossover study with 
healthy volunteers aimed to investigate the effect of clini-
cally used doses of itraconazole on the pharmacokinetics 
of ibrutinib, and the potential of itraconazole to be used as 
a pharmacokinetic booster, allowing the use of smaller and 
more predictable doses of ibrutinib in the clinical practice. 
For safety reasons, only a 15-mg ibrutinib dose was used 




Eleven healthy nonsmoking male volunteers (age range 
19–38 years; body mass index range, 20.7–28.6 kg/m2) par-
ticipated in the study after giving written informed consent. 
Their health was ascertained by medical history, clinical ex-
amination, laboratory tests, and electrocardiogram before 
entering the study. None of the participants used any con-
tinuous medication, and all had normal hemoglobin values 
and prothrombin time.
Study design
The study protocol was approved by the Local Ethics 
Committee of the Helsinki and Uusimaa Hospital District 
(record number HUS/93/2018), and the Finnish Medicines 
Agency, Fimea (EudraCT number 2016-000150-36). In a 
randomized, placebo-controlled, 2-phase crossover study 
with a washout period of 4 weeks, the participants ingested 
either 200  mg itraconazole (Sporanox 100  mg capsule; 
Janssen-Cilag, Espoo, Finland) or placebo capsules con-
taining microcrystallized cellulose at 8 am and 8 pm on day 
1, and at 8 am on days 2–4. On day 3, following an overnight 
fast, itraconazole or placebo was administered at 8 am. At 
9 am, participants took a single oral dose of ibrutinib with 
150 mL of water. The doses of ibrutinib (Imbruvica 140 mg 
capsule; Janssen-Cilag International NV, Beerse, Belgium) 
in the itraconazole and placebo phases were 15 mg and 
140  mg, respectively. The 15-mg ibrutinib capsules were 
prepared by emptying the contents of Imbruvica cap-
sules and mixing the powder with a sufficient amount of 
microcrystallized cellulose by HUS Pharmacy (Helsinki 
University Hospital, Helsinki, Finland). The ibrutinib content 
of the capsules was measured using the liquid chroma-
tography-tandem mass spectrometry system described 
below. On the days of ibrutinib administration, a standard 
breakfast was served immediately after the administration 
of pretreatment, and a warm meal 3 hours and snacks 7 
and 10  hours after ibrutinib ingestion. The use of other 
drugs was prohibited from 1 week before to 1 week after 
the study, along with the use of grapefruit products and 
alcohol for 3 days before and during the study.
Timed blood samples for drug concentration measure-
ments were drawn prior to the administration of pretreatment, 
and 5 minutes before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 11, 23, 
and 47 hours after ibrutinib ingestion into tubes containing 
EDTA. The sample tubes were placed on ice immediately 
thereafter, and plasma was separated within 30 minutes and 
stored at −70°C until analysis.
Determination of drug concentrations
The plasma samples were prepared by use of Phree phos-
pholipid removal plate in 96-well format (Phenomenex, 
Torrance, CA) according to manufacturer recommenda-
tions. In short, plasma was mixed with acetonitrile containing 
1% formic acid and a deuterium-labeled internal standard, 
ibrutinib-d5 or itraconazole-d5 and hydroxyitraconazole-d5. 
The mixture was then drawn through the cartridge, evap-
orated to dryness in a centrifugal evaporator (GeneVac; 
Thermo Fisher Scientific, Waltham, MA), and reconstituted 
in 20% acetonitrile.
Ibrutinib and PCI-45227. The plasma ibrutinib and its active 
metabolite, PCI-45227, were quantified using a Qtrap5500 
liquid chromatography-tandem mass spectrometry system 
(AB Sciex, Toronto, Canada). The mobile phase consisted of 
0.1% formic acid and acetonitrile, and the chromatography 
was performed on a Luna C18 analytical column (2.1 × 100 mm 
inner diameter, 1.6 µm particle size; Phenomenex) operating at 
30°C. The separation was achieved in 5 minutes using a linear 
gradient from 20 to 77% of acetonitrile at constant 300 µL/
minute flow rate. The mass spectrometer was operated in 
positive multiple reaction-monitoring mode with electrospray 
ionization. Ibrutinib and PCI-45227 were monitored at mass-
to-charge ratio (m/z) 441 to 304 and m/z 475 to 304, and the 
lower limits of quantification were 0.05 ng/mL and 0.1 ng/mL, 
respectively. The inter-day precisions (coefficient of variation 
(CV)) were below 9% at relevant plasma drug concentrations 
for both analytes.
Itraconazole and hydroxyitraconazole. Drug concentra-
tions were determined by using a Shimadzu Nexera liquid 
chromatography system (Shimadzu, Kyoto, Japan) coupled 
to an API 3000 tandem mass spectrometer (AB Sciex). 
The chromatographic separation of the analytes was 
accomplished on a Kinetex C18 column (2.1 × 50 mm inner 
diameter, 2.6 µm particle size; Phenomenex) equipped with 
a Kinetex C18 pre-column (2.1  ×  10  mm inner diameter, 
2.6 µm particle size; Phenomenex).
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The mobile phase was composed of 0.1% formic acid 
in water and 0.1% formic acid in acetonitrile, and gradi-
ent program was set from 35 to 95% of organic phase 
over 5 minutes, giving a total run time of 8.1 minutes. The 
mobile phase flow was set at 200 µL/minute and the injec-
tion volume was 10 µL. The mass spectrometry detection 
was performed using electro-spray ionization in positive 
mode, based on the ion transitions m/z 705 to 392 for 
itraconazole and m/z 721 to 408 for hydroxyitraconazole. 
The lower limits of quantification for itraconazole and hy-
droxyitraconazole were 1  ng/mL and 5  ng/mL, and the 
inter-day CVs were below 10% for both analytes at rele-
vant concentrations.
Pharmacokinetics
The pharmacokinetic calculations were performed for 
both the unadjusted ibrutinib and PCI-45227 concen-
trations  and those adjusted to a 140-mg dose. The 
peak plasma concentration (Cmax), time to Cmax (Tmax), 
elimination half-life (t1/2), 0–23-hour area under the con-
centration-time curve (AUC0–23  hours), and AUC from 
zero to infinity (AUC0–∞) were calculated with standard 
noncompartmental methods using Phoenix WinNonlin, 
version 6.4 (Certara, Princeton, NJ). For itraconazole 
and hydroxyitraconazole, the  Cmax, AUC0–5  hours, and 
AUC0–24 hours were calculated.
Genotyping
Genomic DNA was extracted from buffy coats prepared 
from EDTA samples collected for pharmacokinetic analy-
ses, using the Maxwell 16 LEV Blood DNA Kit on a Maxwell 
16 Research automated nucleic acid extraction system 
(Promega, Madison, WI). All participants were genotyped 
for the CYP3A4*22 (rs35599367) and CYP3A5*3 (rs776746) 
single nucleotide variations with TaqMan genotyping as-
says on a QuantStudio 12K Flex Real-Time PCR system 
(ThermoFisher Scientific).
One of the subjects had the CYP3A5*1/*3 genotype 
(CYP3A5 expressor) and the rest had the CYP3A5*3/*3 gen-
otype. None of the subjects had the CYP3A4*22 allele. No 
statistical analysis of genotype data was performed due to 
the small sample size.
Statistical analyses
Based on the pharmacokinetic results of previous studies, 
12 participants were estimated to be adequate to detect 
a 30% difference in the AUC of ibrutinib between the pla-
cebo and itraconazole (with dose-adjustment for ibrutinib) 
phases, with a power of at least 80% (α level 5%). The re-
sults are expressed as geometric means and geometric 
mean ratios with geometric CV or 90% confidence intervals 
(CIs) unless stated otherwise. The pharmacokinetic vari-
ables, except Tmax, were logarithmically transformed before 
analysis. The pharmacokinetic variables (other than Tmax) 
were compared by repeated-measures analysis of variance 
with treatment phase as a within-subject factor. The Tmax 
data were compared using the Wilcoxon signed rank test. 
Correlations were examined using Pearson’s correlation 
coefficients. Statistical analyses were performed using IBM 
SPSS Statistics for Windows version 22.0 (IBM, Armonk, 
NY). Differences were considered statistically significant 
when the P value was < 0.05.
Table 1 Pharmacokinetic variables of ibrutinib and its metabolite PCI-45227 in 11 healthy subjects after a single 140-mg (placebo phase) or  
15-mg (itraconazole phase; both unadjusted and dose-adjusted values given) oral dose of ibrutinib on day 3 of a 4-day pretreatment with 














ratio (90% CI) P value
Ibrutinib
Cmax (ng/mL) 22.0 (0.99) 20.6 (0.53) 0.94 (0.68, 1.30) 0.727 192.2 (0.53) 8.8 (6.34, 12.1) < 0.001
Tmax (hour) 2 (1–4) 3 (1–4) — 0.287 — — —
t1/2 (hour) 4.7 (0.30) 3.8 (0.28) 0.82 (0.72, 0.93) 0.017 — — —
AUC0–23 hours (ng·hour/mL) 74.4 (1.04) 80.9 (0.55) 1.09 (0.79, 1.50) 0.648 755.3 (0.55) 10.2 (7.35, 14.0) < 0.001
AUC0–∞ (ng·hour/mL) 76.5 (1.04) 81.9 (0.55) 1.07 (0.77, 1.49) 0.719 764.0 (0.55) 10.0 (7.18, 13.9) < 0.001
PCI-45227
Cmax (ng/mL) 31.1 (0.33) 2.3 (0.28) 0.07 (0.06, 0.09) < 0.001 21.2 (0.28) 0.68 (0.59, 0.79) < 0.001
Tmax (hour) 3 (1.5–4) 3 (1.5–4) — 0.140 — — —
t1/2 (hour) 6.4 (0.27) 8.1 (0.28) 1.3 (1.10, 1.46) 0.014 8.1 (0.28) 1.3 (1.10, 1.46) 0.014
AUC0–23 hours (ng·hour/mL) 235.2 (0.43) 23.0 (0.36) 0.10 (0.08, 0.11) < 0.001 214.3 (0.36) 0.91 (0.78, 1.07) 0.307
AUC0-∞ (ng·hour/mL) 262.8 (0.45) 27.4 (0.42) 0.10 (0.09, 0.12) < 0.001 256.0 (0.42) 0.97 (0.82, 1.16) 0.792
PCI-45227/Ibrutinib
AUC0-∞ ratio
3.4 (0.57) 0.34 (0.28) 0.10 (0.08, 0.12) < 0.001 — — —
Ibrutinib + active metabolitea 
AUC0-∞ (ng·hour/mL) 95.9 (0.89) 83.8 (0.55) 0.87 (0.66, 1.15) 0.400 781.7 (0.55) 8.2 (6.17, 10.8) < 0.001
Data are given as geometric mean with geometric coefficient of variation, Tmax as median with range. The geometric mean ratios between the two phases 
are given with 90% confidence interval. 
CI, confidence interval; Cmax, peak plasma concentration; Tmax, time to Cmax; t1/2, elimination half-life; AUC0–23 hours, area under the plasma concentration-time 
curve from time 0 to 23 hours; AUC0–∞, area under the plasma concentration-time curve from time from zero to infinity.
aActive metabolite is defined as 1
15
 of PCI-45227 AUC0-∞.
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RESULTS
All enrolled 11 subjects completed the study, and no adverse 
effects were reported or observed. Itraconazole markedly in-
creased the plasma concentrations of ibrutinib and reduced 
their interindividual variation (Table 1, Figures 1 and 2).
Dose-adjusted ibrutinib pharmacokinetics
Itraconazole increased the dose-adjusted geometric mean 
AUC0–∞ and Cmax of ibrutinib (concentrations adjusted to a 
140-mg dose) 10.0-fold (90% CI 7.2–13.9; P < 0.001) and 
8.8-fold (90% CI 6.3–12.1; P < 0.001), respectively (Table 1, 
Figure 1a). An increase in the AUC0–∞ values was observed 
in all participants and the extent of interaction varied greatly 
from 2.9 to 26.6-fold. The metabolite PCI-45227/Ibrutinib 
AUC0–∞ ratio was decreased by itraconazole to 10% (90% 
CI 8–12%; P  < 0.001) of control. In addition, a significant 
correlation (Pearson two-tailed, r2 = 0.93; P < 0.001) was 
seen between the fold-change in ibrutinib AUC0–∞ and 
the  PCI-45227/ibrutinib AUC0–∞ ratio in the placebo 
phase (Figure 3a).
Unadjusted ibrutinib pharmacokinetics
For the unadjusted pharmacokinetics (15 mg ibrutinib during 
itraconazole, 140 mg ibrutinib during placebo), similar ex-
posures to ibrutinib were seen in both phases (Figure 1b). 
The geometric mean ratios of ibrutinib mean AUC0–∞ and 
Cmax between the itraconazole and placebo phases were 
1.07 (90% CI 0.77–1.49; P = 0.719) and 0.94 (90% CI 0.68–
1.30; P = 0.727), respectively (Table 1). The geometric CVs 
of the ibrutinib mean AUC0–∞ and Cmax during the itracon-
azole phase (0.55 and 0.53, respectively) were around half 
of those during the placebo phase (1.04 and 0.99, respec-
tively). Itraconazole shortened the ibrutinib mean t1/2 from 
4.7 to 3.8 hours (P = 0.017). During the itraconazole phase, 
the AUC0-∞ and Cmax of the ibrutinib metabolite PCI-45227 
were 10% (P < 0.001) and 7% (P < 0.001) of those in the 
placebo phase, respectively (Figure 4b).
Itraconazole pharmacokinetics and the extent of 
interaction
The geometric means for itraconazole AUC0–24  hours and 
Cmax on day 3 were 4.7 (CV 0.42) µg·hour/mL and 0.39 (CV 
0.41) µg/mL, respectively, and those of hydroxyitracon-
azole were 13.5 (CV 0.34) µg·hour/mL and 0.73 (CV 0.27) 
µg/mL, respectively. There was no correlation between the 
fold-change in ibrutinib AUC0–∞ and itraconazole pharma-
cokinetics,  i.e., its AUC0–5  hours, which  coincides with the 
absorption phase of ibrutinib (Figure 3b) nor its AUC0–24 hours 
or the sum AUC0–5 hours or AUC0–24 hours of itraconazole and 
hydroxyitraconazole (data not shown).
DISCUSSION
Ibrutinib, an oral inhibitor of BTK, has shown considerable 
single-agent efficacy in CLL.12–14 However, the high cost of 
long-term ibrutinib treatment together with potential adverse 
effects has raised concerns.15 The use of a CYP3A4 inhib-
itor, such as itraconazole, as a pharmacokinetic booster 
could offer a tool to improve ibrutinib bioavailability and re-
duce the financial burden of ibrutinib treatment without the 
risk of compromising its therapeutic plasma concentrations.
The pharmacokinetics of ibrutinib is characterized by 
a low and variable oral bioavailability, due to its extensive 
intestinal and hepatic first-pass metabolism by CYP3A4 
and its flow-dependent hepatic clearance.3–5 Accordingly, 
ibrutinib is very sensitive to drug interactions caused by 
CYP3A inhibitors and inducers,3,6,8 and even food ingestion 
can markedly increase its exposure.4,7 There is evidence 
suggesting that concurrent use of CYP3A4 interacting med-
ications with ibrutinib without dose-adjustment results in 
treatment interruptions and shortened survival.16 Because 
many of the patients using ibrutinib also need other con-
comitant drugs, and because its therapeutic range is limited, 
the effect of other treatments on ibrutinib exposure should 
be as predictable as possible. Accordingly, dosing recom-
mendations on the use of ibrutinib with different CYP3A4 
Figure 1 The plasma concentrations of ibrutinib in a randomized 
crossover study in 11 healthy subjects after a single 140-
mg (placebo phase) or 15-mg (itraconazole phase) oral dose 
of ibrutinib on day 3 of a 4-day pretreatment with 200  mg 
itraconazole or placebo twice daily on day 1 and once daily on 
days 2–4. Data are given for both the ibrutinib concentrations 
adjusted to a 140-mg dose (a) and the unadjusted concentrations 
(b) and are presented as geometric means with 90% confidence 
intervals. For clarity, some error bars have been omitted. Insets 
depict the same data on a semilogarithmic scale.
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perpetrators should be based on the most reliable evidence 
available.3,17
In the present study in healthy subjects, the exposure to 
ibrutinib after a 15-mg oral dose taken concomitantly with 
itraconazole was very close to the exposure after a 140-mg 
ibrutinib dose alone. Accordingly, the effect of itraconazole 
on ibrutinib pharmacokinetics was strong, and there was a 
10-fold mean increase in the dose-adjusted AUC of ibrutinib 
by itraconazole. The interaction was probably caused by in-
hibition of CYP3A4 during the absorption phase of ibrutinib, 
as the t1/2 of ibrutinib was not prolonged. The mechanism of 
the slight shortening of t1/2 is not known. Because ibrutinib 
is a high extraction drug, food increases its oral bioavail-
ability likely by increasing hepatic perfusion and decreasing 
hepatic extraction. In this study, breakfast was served be-
fore ibrutinib ingestion to mimic the usual daily-life situation. 
The effect of food can explain the smaller fold-increase in 
the exposure to ibrutinib than what was expected based on 
previous physiologically-based pharmacokinetic modeling 
(21-fold increase in AUC), which assumed a fasted state.11
The dosages of ibrutinib in this study were smaller than 
those in clinical practice, particularly in the itraconazole 
phase, to avoid unnecessarily high exposure of healthy 
subjects to the potentially toxic study drug. The use of 
dose-adjustment for ibrutinib was justified because  its 
pharmacokinetics are linear.18 Moreover, the pharmaco-
kinetic characteristics of ibrutinib have been shown to be 
similar in healthy subjects and in patients,7 indicating that 
extrapolation of our results to patients is straightforward.
According to prescribing information, the use of ibrutinib 
concomitantly with strong inhibitors of CYP3A4 should be 
avoided unless the benefit outweighs the risk.3 However, dose 
recommendations for the concomitant use of ibrutinib with the 
CYP3A4 inhibitors voriconazole and posaconazole as well as 
moderate CYP3A inhibitors have been given.3 According to 
the European Medicines Agency summary of product char-
acteristics, if a strong CYP3A4 inhibitor must be used, the 
treatment with ibrutinib should be either withheld temporarily 
or its dose should be reduced to 140 mg.17 Our results sug-
gest that the reduced 140-mg dose of ibrutinib is too high 
when used concomitantly with itraconazole, and that about 
one-tenth of the regular treatment dose of ibrutinib (420 mg 
or 560 mg) would result in optimal therapeutic plasma con-
centrations when used with itraconazole. The activity of the 
main metabolite of ibrutinib, PCI-45227, is marginal. Thus, the 
reduction in PCI-45227 AUC0-∞ by itraconazole should not in-
fluence the dose recommendation as indicated by the AUC0-∞ 
of active compounds (ibrutinib + 1
15
 of PCI-45227) (Table 1). 
Of note, the fold-increase in ibrutinib AUC showed no correla-
tion with itraconazole pharmacokinetics. This indicates that 
Figure 2 The unadjusted individual plasma concentration-time curves of ibrutinib in placebo (a) and itraconazole (b) phases, as well 
as the unadjusted individual area under the plasma concentration time curves from zero to infinity (AUC0–∞) (c) and peak plasma 
concentrations (Cmax) (d) of ibrutinib in placebo and itraconazole phases with 90% confidence intervals. Eleven healthy subjects 
received in a randomized crossover study either a single 140-mg (placebo phase) or 15-mg (itraconazole phase) oral dose of ibrutinib 
on day 3 of a 4-day pretreatment with 200 mg itraconazole or placebo twice daily on day 1 and once daily on days 2–4. The bold lines 
in figures (a) and (b) represent the geometric means.
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the inhibition of presystemic CYP3A4-mediated metabolism 
by itraconazole was nearly maximal and is not susceptible 
to moderate changes in itraconazole doses or interindividual 
variability in its pharmacokinetics.
The exposure to ibrutinib varies greatly with standard dos-
ing. In this study, the intersubject CV values for both the Cmax 
and AUC of ibrutinib were reduced from about 100% in the 
placebo phase to 55% in the itraconazole phase. Hence, ex-
tremely high or low ibrutinib concentrations could be avoided 
by using itraconazole with appropriately reduced ibrutinib 
doses. Of interest, the extent of the interaction correlated 
with the metabolite-to-parent AUC ratio in the placebo phase 
(Figure 3a; i.e., the interaction was greatest in individuals with 
a high rate of ibrutinib metabolism). Similar findings have been 
observed in the ketoconazole-ibrutinib interaction study.6 
Accordingly, the high interindividual variability seems to be re-
lated to differences in CYP3A activity in the intestine and liver 
as well as to variation in hepatic blood flow, and it is possible 
to considerably reduce this variability by CYP3A4 inhibitors.
Patients with hematologic disorders are prone to in-
fections due to impaired immunity related either to the 
disease itself or to its treatments. Therefore, antifungal 
prophylaxis is widely used in this patient population in 
high-risk situations. A high number of invasive fungal in-
fections, in particular invasive aspergillosis with frequent 
cerebral involvement, has been reported in patients treated 
with ibrutinib.19–21 However, antifungal prophylaxis in pa-
tients using ibrutinib is considered problematic because 
many antifungal agents interact strongly with ibrutinib.21,22 
Voriconazole is effective in the treatment of invasive fungal 
infections but it is generally not recommended for primary 
prophylaxis.23,24 Itraconazole and fluconazole can be used 
to reduce the incidence of invasive fungal infections, al-
though in high-risk hematologic patients their efficacy 
is weaker than that of posaconazole.23–25 Accordingly, 
itraconazole could be an alternative to fluconazole in the 
prevention of fungal infections in low-risk patients on ibru-
tinib treatment when used together with greatly reduced 
ibrutinib doses. It should be noted that itraconazole may 
also increase plasma concentrations of other drugs, which 
are substrates of CYP3A4 or P-glycoprotein. However, its 
Figure 3 The correlation of the PCI-45227:ibrutinib area under 
the plasma concentration time curve from zero to infinity (AUC0–∞) 
ratio in the placebo phase with the ibrutinib AUC0–∞ itraconazole 
to control ratio (a), and the correlation of itraconazole AUC0–5 hours 
with the ibrutinib AUC0–∞ itraconazole to control ratio (b).
Figure 4 The plasma concentrations of ibrutinib's metabolite 
PCI-45227 in a randomized crossover study in 11 healthy 
subjects after a single 140-mg (placebo phase) or 15-mg 
(itraconazole phase) oral dose of ibrutinib on day 3 of a 4-day 
pretreatment with 200  mg itraconazole or placebo twice daily 
on day 1 and once daily on days 2–4. Data are given for both 
the ibrutinib concentrations adjusted to a 140-mg dose (a) as 
well as the unadjusted concentrations (b) and is presented as 
geometric means with 90% confidence intervals. For clarity, 
some error bars have been omitted. Insets depict the same data 
on a semilogarithmic scale.
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drug interactions are well-documented, and can often be 
managed with dose adjustments.
Compared with conventional chemotherapy, ibrutinib is gen-
erally well-tolerated, but some serious adverse effects, such 
as cytopenias, major bleeding, atrial fibrillation, and infectious 
complications, have been described in relation to its use.3,26 
In a retrospective study of 616 patients with CLL, 41% of the 
patients discontinued ibrutinib, with intolerance rather than CLL 
progression being the major cause of discontinuation.26 In an-
other recent retrospective analysis, major bleeding occurred in 
19% of patients receiving ibrutinib.27 Inhibition of other kinases 
than BTK has been suggested to be involved in some of these 
adverse effects, such as inhibitory effect on platelet function.28 
Based on our present results, the concomitant use of cur-
rently available 70-mg and 140-mg capsules of ibrutinib with 
itraconazole or other strong CYP3A4 inhibitors increases ibru-
tinib exposure to a higher level than what is observed when the 
usual 420-mg or 560-mg daily doses are taken without CYP3A4 
inhibitors. Such a high exposure could increase the risk of 
concentration-dependent adverse effects and lead to discontin-
uation of the treatment and potentially affect clinical outcomes.
In conclusion, co-administering itraconazole as a phar-
macokinetic booster with a markedly lowered ibrutinib dose 
may offer advantages. First, by knowing the extent of the 
interaction, a smaller dose of ibrutinib can be used together 
with itraconazole. This could serve as a cost-effective means 
to provide efficient treatment to a larger number of patients 
as the financial burden is lessened. Second, itraconazole 
reduces the interindividual variation in the exposure to ibru-
tinib. This provides more predictable pharmacokinetics, 
which potentially results in more reliable efficacy and less 
adverse effects. Third, because patients treated with ibruti-
nib are more prone to fungal infections, itraconazole could 
give patients some prophylaxis against fungal infections.
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